SAMS and Aquapharm sign marine products agreement
AQUAPHARM Biodiscovery, a leading marine biotechnology company, has announced it has signed a long-term agreement with the Scottish Association for Marine Science (SAMS) to discover, develop and launch new marine products derived from marine micro-organisms.
Under the terms of this agreement, SAMS will provide Aquapharm with privileged access to the vast array of marine samples that it has collected from diverse marine habitats around the globe. Aquapharm will then apply its extensive culturing and marine fermentation know-how to these samples to capture and harness the full microbial biodiversity that they contain, further expanding the scope of its collection of marine micro-organisms.
Once Aquapharm has cultured and identified the range of novel microbial species present in these samples, it will draw out their unique biochemistry through the application of its suite of screening technologies, including SeaRch™, in some cases activating otherwise inaccessible, dormant biosynthetic pathways to produce a cocktail of chemical diversity that Aquapharm will convert into candidate functional ingredients or pharmaceuticals.